Disease or Syndrome
Amylyx’s ALS Treatment Relyvrio Disappoints in Phase III PHOENIX Study, Company Considering Market Withdrawal
Amylyx, Relyvrio, ALS, Failure, Phase III PHOENIX Study, Market Withdrawal, Clinical Trial, Placebo, No Statistical Significance
FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment
Overall Survival, Combined, cisplatin, Opdivo
Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.
Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction
Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy
Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment
Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline
NBD1 stabilizers, ICL4 inhibitor, Cystic fibrosis, CFTR, NBD1, Cystic fibrosis, Cystic fibrosis, Sionna, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic Cystic, Cystic Cystic Cystic:, Search for the citation:
Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial
Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile
Sandoz Wins Historic FDA Approval for First Two Interchangeable Denosumab Biosimilars Targeting Amgen’s Blockbuster Bone Therapy
Sandoz, FDA approval, Denosumab biosimilars, Wyost, Jubbonti, Interchangeable, Prolia, Xgeva, Amgen, Osteoporosis, Bone metastases, Cancer-related skeletal events, Patent litigation
Novo Nordisk’s Ozempic Shows Promising Kidney Benefits for Diabetic Patients
Ozempic, Novo Nordisk, Chronic kidney disease, Cardiovascular events, Expanded use, Semaglutide, FLOW trial, Reduced risk, Type 2 diabetes
“Regulating Hope Amidst Uncertainties: Novel ALS Treatments Face Complex Challenges”
ALS Treatments, Regulatory Uncertainty, Clinical Trials, Relyvrio, Masitinib, Antisense Therapy, Risk-Benefit Analysis, FDA Approval, Patient Advocacy
Sarepta’s ELEVIDYS Gaining Ground Amidst Anticipation for Expanded Label Approval
ELEVIDYS, Age, Muscular Dystrophy, Duchenne, Sarepta, Labels (device), Child